US prevalence
~25% of US adults
Source: AASLD
Condition
NAFLD / MASLD (Fatty Liver Disease)
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects 25-30% of US adults. GLP-1 and GLP-1/GIP agonists show robust reductions in liver fat. Wegovy (semaglutide 2.4 mg) was FDA-approved in August 2025 for MASH with moderate-to-advanced (F2–F3) liver fibrosis — the first GLP-1 approved for a liver disease — based on the phase 3 ESSENCE trial (MASH resolution and fibrosis-improvement endpoints met). Resmetirom (Rezdiffra) was the first MASH-specific drug (approved 2024). Tirzepatide showed similar liver-fat and fibrosis improvements in SYNERGY-NASH but is not yet FDA-approved for MASH. Evidence grade: A (phase 3 RCT for semaglutide). Outside the Wegovy MASH indication, GLP-1s are used off-label or based on coexisting obesity/T2D indications.
Quick answer
UpdatedNon-alcoholic fatty liver disease (NAFLD) — recently renamed MASLD (metabolic dysfunction-associated steatotic liver disease) — affects ~25% of US adults. It is the most common liver disease, strongly linked to obesity, T2D, and insulin resistance. ~20% of NAFLD patients develop NASH (steatohepatitis) which can progress to cirrhosis. GLP-1 medications reduce liver fat and inflammation, and in August 2025 Wegovy (semaglutide) became the first GLP-1 FDA-approved for MASH with moderate-to-advanced (F2–F3) fibrosis, based on the phase 3 ESSENCE trial.
- US prevalence: ~25% of adults (~80 million)
- AASLD epidemiologic data
- NASH progression: ~20% of NAFLD progresses to NASH
- Cirrhosis risk in subset
- Semaglutide trial: Significant NASH resolution at 72 weeks
- Phase 2 trial, Newsome et al NEJM 2021
- Tirzepatide trial: SYNERGY-NASH positive
- Fibrosis/liver-fat gains; not yet FDA-approved for MASH
- FDA-approved for MASH: Wegovy (2025) & Resmetirom (2024)
- Wegovy = first GLP-1 for MASH, F2–F3 fibrosis
Last clinical review
By GLP1Zoom editorial board
GLP-1 role
Wegovy (semaglutide) is FDA-approved for MASH with F2–F3 fibrosis (Aug 2025) via the phase 3 ESSENCE trial — the first GLP-1 approved for liver disease. Tirzepatide showed similar benefit in SYNERGY-NASH but is not yet approved for MASH. Off-label GLP-1 use is common in MASH patients with obesity/T2D.
Key takeaways
- • Wegovy (semaglutide) is FDA-approved for MASH with F2–F3 fibrosis (Aug 2025) — the first GLP-1 approved for a liver disease.
- • The approval was based on the phase 3 ESSENCE trial (MASH resolution + fibrosis improvement endpoints met).
- • Resmetirom (Rezdiffra) was the first MASH-specific drug (2024); Wegovy followed in 2025. Tirzepatide is promising but not yet MASH-approved.
- • Use of GLP-1s for fatty liver is off-label; coverage is typically driven by T2D or obesity comorbidity.
- • Always pair with hepatology workup — FibroScan, liver enzymes, FIB-4 index.
Key facts
- •Newsome et al. (2021, NEJM): semaglutide 0.4 mg daily achieved NASH resolution without fibrosis worsening in 59% vs 17% placebo.
- •SYNERGY-NASH (2024): tirzepatide reduced liver fat and improved fibrosis biomarkers in adults with biopsy-proven MASH.
- •ESSENCE (2024 topline): semaglutide 2.4 mg met both MASH resolution and fibrosis improvement primary endpoints in phase 3.
Why GLP-1 medications
Wegovy (semaglutide 2.4 mg) was FDA-approved in August 2025 for MASH with moderate-to-advanced (F2–F3) liver fibrosis — the first GLP-1 approved for a liver disease — based on the phase 3 ESSENCE trial (MASH resolution and fibrosis-improvement endpoints met). Resmetirom (Rezdiffra) was the first MASH-specific drug (approved 2024). Tirzepatide showed similar liver-fat and fibrosis improvements in SYNERGY-NASH but is not yet FDA-approved for MASH. Evidence grade: A (phase 3 RCT for semaglutide). Outside the Wegovy MASH indication, GLP-1s are used off-label or based on coexisting obesity/T2D indications.
GLP-1 drugs prescribed for NAFLD / MASLD (Fatty Liver Disease)
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Wegovy$1349–$1500/mo
semaglutide
75/100 matchOff-label for NAFLD/MASLD — semaglutide showed liver-fat reduction in trials
Compare providers - Zepbound$349–$1086/mo
tirzepatide
75/100 matchOff-label for NAFLD/MASLD — emerging evidence for steatohepatitis benefit
Compare providers - Ozempic$968–$1100/mo
semaglutide
70/100 matchOff-label for NAFLD; on-label for type 2 diabetes which frequently coexists
Compare providers - Mounjaro$1023–$1330/mo
tirzepatide
75/100 matchOff-label for NAFLD; on-label for type 2 diabetes which frequently coexists
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Wegovy semaglutide | $1349–$1500/mo | 75/100 | Off-label for NAFLD/MASLD — semaglutide showed liver-fat reduction in trials | Compare |
| Zepbound tirzepatide | $349–$1086/mo | 75/100 | Off-label for NAFLD/MASLD — emerging evidence for steatohepatitis benefit | Compare |
| Ozempic semaglutide | $968–$1100/mo | 70/100 | Off-label for NAFLD; on-label for type 2 diabetes which frequently coexists | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 75/100 | Off-label for NAFLD; on-label for type 2 diabetes which frequently coexists | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Compare telehealth providers for NAFLD / MASLD (Fatty Liver Disease)
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Ro· from $145/moHighest score in our rubricTelehealth · NAFLD / MASLD (Fatty Liver Disease) care
- Hers· from $99/moFDA-approved brand medicationTelehealth · NAFLD / MASLD (Fatty Liver Disease) care
- Hims· from $99/moNo video visit requiredTelehealth · NAFLD / MASLD (Fatty Liver Disease) care
- LifeMD· from $89/moBills your insuranceTelehealth · NAFLD / MASLD (Fatty Liver Disease) care
Medications for NAFLD / MASLD (Fatty Liver Disease)
Wegovy
semaglutide
GLP1Zoom score: 8.9/10
From $1349/mo
Ozempic
semaglutide
GLP1Zoom score: 5.8/10
From $968/mo
Compounded Semaglutide
semaglutide (compounded)
GLP1Zoom score: 6.5/10
From $99/mo
Zepbound
tirzepatide
GLP1Zoom score: 9.3/10
From $349/mo
Mounjaro
tirzepatide
GLP1Zoom score: 6.6/10
From $1023/mo
Compounded Tirzepatide
tirzepatide (compounded)
GLP1Zoom score: 6.5/10
From $149/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizNAFLD / MASLD (Fatty Liver Disease)& GLP-1 — frequently asked questions
Can GLP-1 medications treat NAFLD / MASLD (Fatty Liver Disease)?
Wegovy (semaglutide 2.4 mg) was FDA-approved in August 2025 for MASH with moderate-to-advanced (F2–F3) liver fibrosis — the first GLP-1 approved for a liver disease — based on the phase 3 ESSENCE trial (MASH resolution and fibrosis-improvement endpoints met). Resmetirom (Rezdiffra) was the first MASH-specific drug (…
Which GLP-1 medications are used for NAFLD / MASLD (Fatty Liver Disease)?
GLP-1 options associated with NAFLD / MASLD (Fatty Liver Disease) include Wegovy, Zepbound, Ozempic, Mounjaro, Compounded Semaglutide. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for NAFLD / MASLD (Fatty Liver Disease)?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for NAFLD / MASLD (Fatty Liver Disease) or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly for Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Diagnostic algorithm
How NAFLD/MASLD is diagnosed
Who diagnoses: Primary care provider, hepatologist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
Risk factor identification
Obesity, T2D, metabolic syndrome, age >50
Threshold: BMI ≥30 alone is sufficient indication to screen
- 2
Liver function panel
ALT, AST, GGT, alkaline phosphatase
Threshold: ALT elevation common but not required for diagnosis
- 3
Imaging
Ultrasound (initial), CT or MRI for inconclusive cases, transient elastography (FibroScan) for fibrosis
Threshold: Steatosis seen on imaging confirms NAFLD; fibrosis = MASH risk
- 4
Exclude alternative causes
Hepatitis B/C serology, alcohol history, autoimmune workup, iron studies
Threshold: Alcohol <14 drinks/week (women) or <21 (men) = non-alcoholic etiology
- 5
Fibrosis staging
FIB-4 score + NAFLD Fibrosis Score + elastography
Threshold: FIB-4 >2.67 = high fibrosis risk; biopsy may be considered
Source: AASLD Practice Guidance (2024)
Treatment decision criteria
When does a GLP-1 fit NAFLD / MASLD (Fatty Liver Disease)?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- Concurrent obesity (primary indication)
- Concurrent T2D
- MASH (steatohepatitis) with significant fibrosis — semaglutide Phase 2 evidence
- Failed lifestyle intervention + Mediterranean diet
Try alternatives first if…
- NAFLD without significant inflammation (simple steatosis)
- Patient achieving 7-10% weight loss via lifestyle alone
- MASH-specific therapy preferred (resmetirom FDA-approved 2024)
- Pregnancy or planning
First-line alternatives for NAFLD / MASLD (Fatty Liver Disease)
- Resmetirom
- FDA-approved 2024 specifically for MASH with significant fibrosis
- Lifestyle intervention
- 7-10% weight loss reverses MASH in many patients
- Mediterranean diet
- Evidence-based dietary pattern for NAFLD
- Vitamin E (specific patients)
- For non-diabetic MASH per AASLD guidelines
Authoritative sources on NAFLD / MASLD (Fatty Liver Disease)
- Nonalcoholic fatty liver disease (NAFLD/MASLD) — NIH — NIDDK